Rapport Therapeutics, Inc. RAPP Share of other comprehensive (loss) income from Brookfield Asset Management ULC
Share of other comprehensive (loss) income from Brookfield Asset Management ULC at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OciEquityMethodInvestmentAfterTaxParent.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s share of other comprehensive (loss) income from brookfield asset management ulc.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s share of other comprehensive (loss) income from brookfield asset management ULC?
- Rapport Therapeutics, Inc. (RAPP) reported share of other comprehensive (loss) income from brookfield asset management ULC of -$1.05M in Q1 2026.
- How has Rapport Therapeutics, Inc.'s share of other comprehensive (loss) income from brookfield asset management ULC changed year-over-year?
- Rapport Therapeutics, Inc.'s share of other comprehensive (loss) income from brookfield asset management ULC decreased by 346.1% year-over-year, from $427K to -$1.05M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s share of other comprehensive (loss) income from brookfield asset management ULC?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s share of other comprehensive (loss) income from brookfield asset management ULC has grown at a 1534.0% compound annual growth rate (CAGR), from $4K to $1.07M.
- What does share of other comprehensive (loss) income from brookfield asset management ULC mean?
- This metric captures the company's proportional share of the other comprehensive income or loss generated by an entity accounted for under the equity method. It reflects unrealized gains or losses, such as foreign currency translation adjustments or changes in the fair value of available-for-sale securities, recognized by the investee. This provides insight into the broader financial performance of strategic partnerships beyond standard operating results.